Women taking HT had a significantly decreased incidence of fracture with long-term use .
Research ers found no strong evidence that HT has a clinical ly meaningful impact on the incidence of colorectal cancer .
AUTHORS ' CONCLUSIONS : Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT , provided they do not have specific contraindications .
HT may be unsuitable for some women , including those at increased risk of cardiovascular disease , increased risk of thromboembolic disease ( such as those with obesity or a history of venous thrombosis ) or increased risk of some types of cancer ( such as breast cancer , in women with a uterus ) .
The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well documented .
HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia , nor for prevention of deterioration of cognitive function in postmenopausal women .
Although HT is considered effective for the prevention of postmenopausal osteoporosis , it is generally recommended as an option only for women at significant risk for whom non-oestrogen therapies are unsuitable .
BACKGROUND : Hormone therapy ( HT ) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease , osteoporosis and  dementia in older women .
This is an up date d version of a Cochrane review first published in 2005 .
OBJECTIVES : To assess effects of long-term HT ( at least 1 year 's duration ) on mortality , cardiovascular outcomes , cancer , gallbladder disease , fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment .
Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study
Abstract The study was performed to compare the clinical effect of a hormone replacement therapy ( HRT ) with two different progestins . Postmenopausal women ( PMW ) with climacteric symptoms ( CS ) r and omly received for 12 months orally , either placebo ( n = 20 ) , 1 mg estradiol ( E ) plus 0.5 mg noretisterone acetate ( NETA ; n = 40 ) , or 2 mg drospirenone ( DRSP ; n = 40 ) , a testosterone- and spironolactone-derived molecule , respectively . Weight ( W ) declined only during E/DRSP ( p < 0.04 versus placebo ) . Fat mass ( FM ) decreased , similarly , during E/NETA and E/DRSP . Intracellular water ( ICW ) did not change , while extracellular water ( ECW ) decreased during E/DRSP ( p < 0.0001 ) ( p < 0.002 versus E/NETA ) . During E/NETA and E/DRSP , similar decreases were observed for insulin resistance ( IR ) by the homeostatic model assessment for IR ( HOMA-IR ) ( p < 0.0001 versus placebo for both ) , systolic ( p < 0.04 versus placebo for both ) and diastolic ( p < 0.002 ) blood pressure ( BP ) . Lipids did not change . In comparison to placebo CS , by the Kupperman Index ( KI ) , significantly declined ( p < 0.0001 ) during E/NETA or E/DRSP . Menopause-specific Quality of Life ( MENQoL ) significantly declined versus placebo ( p < 0.04 ) during both E/NETA and E/DRSP . In conclusion , differences between the two progestins are mainly limited to body composition ( BC ) , where the addition of DRSP decreases ECW and body W ( BW )
Women taking HT had a significantly decreased incidence of fracture with long-term use .
Research ers found no strong evidence that HT has a clinical ly meaningful impact on the incidence of colorectal cancer .
AUTHORS ' CONCLUSIONS : Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT , provided they do not have specific contraindications .
HT may be unsuitable for some women , including those at increased risk of cardiovascular disease , increased risk of thromboembolic disease ( such as those with obesity or a history of venous thrombosis ) or increased risk of some types of cancer ( such as breast cancer , in women with a uterus ) .
The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well documented .
HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia , nor for prevention of deterioration of cognitive function in postmenopausal women .
Although HT is considered effective for the prevention of postmenopausal osteoporosis , it is generally recommended as an option only for women at significant risk for whom non-oestrogen therapies are unsuitable .
BACKGROUND : Hormone therapy ( HT ) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease , osteoporosis and  dementia in older women .
This is an up date d version of a Cochrane review first published in 2005 .
OBJECTIVES : To assess effects of long-term HT ( at least 1 year 's duration ) on mortality , cardiovascular outcomes , cancer , gallbladder disease , fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment .